BeiGene, Ltd. (BGNE) PT Raised to $429 at Cowen

February 18, 2021 6:17 AM EST
Get Alerts BGNE Hot Sheet
Price: $292.75 -3.5%

Rating Summary:
    11 Buy, 4 Hold, 3 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 16 | New: 68
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Cowen analyst Yaron Werber raised the price target on BeiGene, Ltd. (NASDAQ: BGNE) to $429.00 (from $348.00) while maintaining an Outperform rating.

The analyst commented, "BeiGene has demonstrated the ability to create value through a robust pipeline and several in-licensed programs. We are increasing our PT to $429 (+$81) based on the lucrative tisle agreement with Novartis and increased conviction in deep oncology pipeline. We see continued success for BeiGene’s global development strategy and best-in-class commercial organization in China."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Cowen & Co